Article

Prognostic significance of Nottingham histologic grade in invasive breast carcinoma.

Department of Histopathology, School of Molecular Medical Sciences, Division of Epidemiology and Public Health, University of Nottingham, Nottingham City Hospital NHS Trust, Hucknall Rd, Nottingham, NG5 1PB United Kingdom.
Journal of Clinical Oncology (Impact Factor: 17.88). 08/2008; 26(19):3153-8. DOI: 10.1200/JCO.2007.15.5986
Source: PubMed

ABSTRACT The three strongest prognostic determinants in operable breast cancer used in routine clinical practice are lymph node (LN) stage, primary tumor size, and histologic grade. However, grade is not included in the recent revision of the TNM staging system of breast cancer as its value is questioned in certain settings.
This study is based on a large and well-characterized consecutive series of operable breast cancer (2,219 cases), treated according to standard protocols in a single institution, with a long-term follow-up (median, 111 months) to assess the prognostic value of routine assessment of histologic grade using Nottingham histologic grading system.
Histologic grade is strongly associated with both breast cancer-specific survival (BCSS) and disease-free survival (DFS) in the whole series as well as in different subgroups based on tumor size (pT1a, pT1b, pT1c, and pT2) and LN stages (pN0 and pN1 and pN2). Differences in survival were also noted between different individual grades (1, 2, and 3). Multivariate analyses showed that histologic grade is an independent predictor of both BCSS and DFS in operable breast cancer as a whole as well as in all studied subgroups.
Histologic grade, as assessed by the Nottingham grading system, provides a strong predictor of outcome in patients with invasive breast cancer and should be incorporated in breast cancer staging systems.

2 Bookmarks
 · 
345 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adenoid cystic carcinomas (ACCs) from various anatomic sites harbor a translocation t(6;9)(q22-23;p23-24), resulting in MYB-NFIB gene fusion. This gene fusion is not well-studied in mammary ACCs and there are no studies examining this abnormality in solid variant of ACC with basaloid features (SBACC), a high-grade variant thought to behave more aggressively than ACCs with conventional histologic growth. Our aim was to investigate the frequency of MYB-NFIB gene fusion in mammary ACCs with a focus paid to SBACC. MYB rearrangement and MYB-NFIB fusion were assessed by fluorescence in situ hybridization (FISH) and RT-PCR, respectively. Histologic features and the presence of MYB rearrangement were correlated with clinical outcome. MYB rearrangement was present in 7 of 31 (22.6%) mammary ACCs [5 of 15 (33.3%) ACCs with conventional growth; 2 of 16 (12.5%) SBACCs]. One patient with conventional ACC developed distant metastasis, and no patients had axillary lymph node involvement by ACC (mean follow-up 34 months, range 12–84 months). Two patients with SBACC had axillary lymph node involvement at initial surgery, and two additional patients experienced disease recurrence (1 local, 1 distant; mean follow-up, 50 months, range 9–192 months). MYB-NFIB fusion status did not correlate with clinical outcome in studied patients. We confirm that MYB-NFIB gene fusion is observed in mammary ACCs and that a subset lacks this abnormality. This study is the first to confirm the presence of MYB rearrangement in SBACC. Additional validation with long-term follow-up is needed to determine the relationship, if any, between MYB-NFIB gene fusion and clinical outcome.
    Human pathology 08/2014; · 2.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZEB1 and ZEB2 have been recently related to cancer prognosis. We investigated their expression and its association with clinicopathological parameters and overall survival in invasive micropapillary carcinoma (IMPC), which is a metastasising neoplasm of the canine mammary gland. Immunohistochemical evaluation showed nuclear and cytoplasmic staining for ZEB2 and nuclear staining for ZEB1. ‘In situ’ areas presented higher positivity for cytoplasmic ZEB2 than invasive areas of IMPC did (p=0.03). ZEB1 positivity was associated with a low histological grade (p=0.01). A shorter overall survival rate was observed in IMPCs that were positive for cytoplasmic ZEB2 (p=0.04). Antibodies specificity in canine species was confirmed by western blot. Our results indicated that cytoplasmic ZEB2 appears to be an important factor in the early stages of malignancy and predicts a poor overall survival rate for IMPC in this canine mammary cancer model. ZEB1 downregulation appears to be associated with the dedifferentiation process of IMPC.
    Research in Veterinary Science 10/2014; · 1.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: As molecular profiling data continues to accumulate, the design of integrative computational analyses that can provide insights into the dynamic aspects of cancer progression becomes feasible. Here, we present a novel computational method for the construction of cancer progression models based on the analysis of static tumor samples. We demonstrate the reliability of the method with simulated data, and describe the application to breast cancer data. Our findings support a linear, branching model for breast cancer progression. An interactive model facilitates the identification of key molecular events in the advance of disease to malignancy.
    Genome Biology 08/2014; 15(8):440. · 10.47 Impact Factor